Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antimicrotubule agents]

H Niitani1, S Hisakatsu

  • 1Forth Dept. of Internal Medicine, Nippon Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

New anticancer agents targeting microtubules are revolutionizing cancer chemotherapy. These agents, including Navelbine, Taxol, Taxotere, and E7010, exhibit distinct mechanisms, offering novel treatment strategies for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid.

Oncology reports·2011
Same author

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

British journal of cancer·2003
Same author

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2002
Same author

A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.

International journal of clinical oncology·2002
Same author

Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.

International journal of clinical oncology·2001
Same author

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.

British journal of cancer·2001

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Microtubules are critical targets for anticancer drugs.
  • Novel antimicrotubule agents are emerging in cancer chemotherapy.
  • Understanding their mechanisms is key to effective treatment.

Purpose of the Study:

  • To review preclinical and clinical results of new antimicrotubule agents.
  • To highlight the distinct mechanisms of action of these novel drugs.
  • To discuss their potential in cancer treatment, particularly non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of preclinical studies.
  • Analysis of clinical trial data.
  • Comparison of drug mechanisms: depolymerization versus polymerization.

Related Experiment Videos

Main Results:

  • Navelbine, a vinca alkaloid derivative, shows activity against NSCLC.
  • Taxol and Taxotere promote tubulin polymerization.
  • E7010, a sulfonamide, inhibits tubulin polymerization.

Conclusions:

  • New antimicrotubule agents offer diverse therapeutic strategies.
  • Distinct mechanisms of action (polymerization vs. depolymerization) provide treatment options.
  • These agents hold promise for improving cancer chemotherapy outcomes.